📌 Key Takeaways
- Topic: Silica Distributor vs Manufacturer: Which Is Better for Your Purchase?
- Keywords: ultrafine silica powder
- Published: 2026-11-20 13:30:26
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
BET Surface Area of Silica: Measurement Method and Typical Values by Grade
- What Is Silica Powder? Types, Particle Sizes, Grades and Common Applications
- What Is TEOS? Uses in Sol-Gel Silica, Coatings and Semiconductors
- So why make a website dedicated to some fossilized deposit?
- Silica as a Thickening Agent: How It Works in Liquids, Resins and Gels
- The skin is our largest organ, which consists of three layers: the epidermis, dermis, and hypodermis. Owing to its big surface zone, it also serves as an essential gateway for drug administration [ 25 ], which is fitting for both local (dermal) or systemic (transdermal) therapy [ 25, 56 ]. In spite of the popularity of this administration route, it is a challenge to get the API into deeper layers of the skin. The outermost layer of the epidermis, the stratum corneum, is the biggest hurdle to molecular penetration [ 25, 56 ]. However, the molecules must be absorbed through the capillaries of the dermis to achieve a systemic impact, which can be facilitated employing nanocarriers [ 56 ]. In addition, sweat glands or hair follicles can be effective alternative routes for the molecules to enter the deeper layers of the skin [ 25, 56 ]. In summary, it can be called as the transappendageal route. Among physicochemical properties, particle size is one of the most vital factors influencing absorption. Particles in the range between 200 and 300 nm are suitable for local treatment of the skin in diseases such as atopic dermatitis [ 25 ] since particles larger than 75 nm do not pass through the stratum corneum [ 25 ]. Smaller particles (approximately 50 nm) are suitable for systemic treatment [ 25 ], and on the whole, it can be said that nanoparticles with a diameter smaller than 25 nm can penetrate the skin most effectively, so they can be used for transdermal drug administration with an appropriate formulation [ 56 ]. By controlling the size of the nanocarrier, they penetrate to different depths in the skin. From the element of surface characteristics, cationic amino-functionalized MSNs show more efficient penetration into deeper layers of the skin than the particles with anionic surfaces of the same size [ 25 ]. The use of MSNs as a drug carrier may improve aqueous solubility, stability, and skin penetration of the drug [ 61 ]. In a research, gels containing MSN were prepared by employing distilled water to form the base, adding the gelling agent (Poloxamer 407), and adding HPMC to enhance the viscosity [ 83 ]. In another publication, MSN containing oleogels were prepared with sunflower oil and the addition of colloidal silicon dioxide as a gelling agent [ 61 ]. According to in vitro experiments, the gel matrix also affected the drug release kinetics [ 61, 83 ]. Slower drug release was observed in the case of gels containing loaded MSNs, compared to the free carriers, and the outcomes demonstrated close to zero-order release kinetics [ 61 ]. According to in vitro biocompatibility studies, this gel complex did not show any evidence of cytotoxicity on dermal fibroblast cells. Moreover, according to in vivo dermal safety studies, it has been proven that this preparation does not cause skin irritation during application, and so this formulation can be considered a safe product [ 61 ].
- Feed Grade Silica: Specifications and Uses as a Carrier and Flow Agent in Animal Feed
Silica as a Toothpaste Abrasive: How It Cleans and How RDA Is Controlled
What is silica (SiO₂)?
silica for sale
What is the difference between fumed silica and precipitated silica?
silica flatting agent
What drives silica raw material prices?
microsilica Targeted therapy, aiming, for instance, at antitumor treatments, can be divided into active and passive forms [ 72, 73 ]. Passive targeting is based on higher vascularity and higher vascular permeability of the tumor, as well as inflamed tissues, compared to physiological ones [ 73, 74 ]. Additionally, the lymphatic circulation of the tumor shows decreased efficiency [ 25 ], which led to easier accumulation of nanoparticles in the tumor or inflamed tissues [ 10, 27, 72, 74 ]. This passive accumulation is normally called "ELVIS" (Extravasation through Leaky Vasculature and later Inflammatory cell-mediated Sequestration) [ 72, 74 ]. From the facet of surface qualities, negatively charged nanoparticles accumulate less effectively inside cells, due to the negatively charged cell membrane, which slows down the cellular uptake, so, in this case, a neutral surface charge is more favorable [ 25 ]. In contrast, active targeting can be accomplished by functionalizing the outer surface of the silica carriers [ 10, 27, 72 ], where molecules are attached to the surface of the carriers that specifically bind to certain cell surface ligands and receptors, which are characteristic of tumor-, but not of healthy cells. This selective method provides more effective treatment and reduces the side impacts of cytotoxic APIs on healthy cells and tissues [ 10, 27 ]. The most recent findings on active targeting possibilities are summarized in Table 3. García-Fernández et al. prepared a mesoporous silica-based nanocarrier loaded with dexamethasone and capped with a particular protein to actively target the TNFR1 receptor, which is overexpressed in pro-inflammatory macrophages [ 72 ]. Since the carriers are preferably internalized by these macrophages, the cargo is released in a controlled manner, during enzymatic hydrolysis, thus preventing premature drug release, thanks to the gatekeepers. The targeting talent was tested in vitro with activated macrophages. On the other hand, the therapeutic efficiency was tested in vivo in mouse models. The researchers observed greater therapeutic impacts and fewer adverse side influences than in the case of free dexamethasone. To sum up, dexamethasone-loaded MSN has been effectively developed to actively target the lungs in acute lung injury (ALI), and this result may also be promising in other lung diseases (COPD, asthma) [ 72 ]. Teruel et al. presented a novel approach in oral inflammatory bowel sickness (IBD) therapy, using functionalized magnetic mesoporous silica microparticles [ 75 ].
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.